These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24360932)

  • 1. Prospective study of continuous infusion with Beriate® P in patients with severe haemophilia A undergoing surgery - a subgroup analysis.
    Auerswald G; Bade A; Johne J; Haubold K; Overberg D; Masurat S; Moorthi C
    Thromb Res; 2014 Nov; 134 Suppl 1():S43-7. PubMed ID: 24360932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A.
    Klamroth R; Gottstein S; Orlovic M; Heinrichs C
    Thromb Res; 2014 Nov; 134 Suppl 1():S38-42. PubMed ID: 24256767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.
    Klamroth R; Holzhauer S; Zimmermann R; Heller C; Kurnik K;
    Thromb Res; 2014 Nov; 134 Suppl 1():S16-21. PubMed ID: 24418255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen safety of Beriate®.
    Gröner A
    Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
    Bidlingmaier C; Deml MM; Kurnik K
    Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of haemophilia A in Tunisia: efficacy and inhibitor study.
    Houissa B; Mliki ML; Abdelkafi S; Bouslama M; Zaïer M; Mahjoub T; Kortas M; Ghachem L; Yacoub S
    Hamostaseologie; 2003 Aug; 23(3):144-8. PubMed ID: 12923586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous infusion in haemophilia: current practice in Europe.
    Batorova A; Holme P; Gringeri A; Richards M; Hermans C; Altisent C; Lopez-Fernández M; Fijnvandraat K;
    Haemophilia; 2012 Sep; 18(5):753-9. PubMed ID: 22530687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
    Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
    Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands.
    Eckhardt CL; Mauser-Bunschoten EP; Peters M; Leebeek FW; van der Meer FJ; Fijnvandraat K
    Br J Haematol; 2012 Jun; 157(6):747-52. PubMed ID: 22533635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
    Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
    Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
    Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of haemophilia patients in East Germany prior to and after reunification in 1990.
    Lenk H
    Thromb Res; 2014 Nov; 134 Suppl 1():S57-60. PubMed ID: 24745720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Klukowska A; Komrska V; Jansen M; Laguna P
    Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.